A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas

Luigi Fedele, Stefano Bianchi, Ricciarda Raffaelli, Giovanni Zanconato

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the effects of two types of hormone replacement therapy, an estrogen-progestin combination and tibolone, on uterine myomas in menopausal women. Study design: Thirty-eight menopausal women with one or more uterine myomas were randomized to treatment with a transdermal system continuously releasing estradiol 50 μg/day combined with oral medroxyprogesterone acetate (MPA) 10 mg/day for 12 days/month or tibolone tablets 2.5 mg/day. The scheduled duration of both treatments was 12 months. Physical examination and abdominal/transvaginal ultrasonography were performed before entering the study and at 3, 6 and 12 months of treatment. At each ultrasonography the overall uterine volume was determined as well as the size of each myoma and the endometrial thickness and characteristics. Results: No statistically significant difference was detected between the two groups at any time during treatment. However, within-group analysis showed a significant increase of uterine volume and of myoma number and size in the estrogen-progestin group, whereas no such increase occurred in the patients treated with tibolone. Also, the mean endometrium width increased significantly from baseline to the end of treatment in the estrogen-progestin group, but not in the tibolone group. Conclusions: Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus and myomas. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)91-94
Number of pages4
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume88
Issue number1
DOIs
Publication statusPublished - Jan 2000

Fingerprint

tibolone
Myoma
Estrogen Replacement Therapy
Progestins
Estrogens
Ultrasonography
Therapeutics
Medroxyprogesterone Acetate
Hormone Replacement Therapy
Endometrium
Tablets
Physical Examination
Uterus
Estradiol

Keywords

  • Hormone replacement therapy
  • Menopause
  • Tibolone
  • Uterine myomas

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. / Fedele, Luigi; Bianchi, Stefano; Raffaelli, Ricciarda; Zanconato, Giovanni.

In: European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 88, No. 1, 01.2000, p. 91-94.

Research output: Contribution to journalArticle

@article{13b818d384db4fcfb033af5dbd1faf6a,
title = "A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas",
abstract = "Objective: To evaluate the effects of two types of hormone replacement therapy, an estrogen-progestin combination and tibolone, on uterine myomas in menopausal women. Study design: Thirty-eight menopausal women with one or more uterine myomas were randomized to treatment with a transdermal system continuously releasing estradiol 50 μg/day combined with oral medroxyprogesterone acetate (MPA) 10 mg/day for 12 days/month or tibolone tablets 2.5 mg/day. The scheduled duration of both treatments was 12 months. Physical examination and abdominal/transvaginal ultrasonography were performed before entering the study and at 3, 6 and 12 months of treatment. At each ultrasonography the overall uterine volume was determined as well as the size of each myoma and the endometrial thickness and characteristics. Results: No statistically significant difference was detected between the two groups at any time during treatment. However, within-group analysis showed a significant increase of uterine volume and of myoma number and size in the estrogen-progestin group, whereas no such increase occurred in the patients treated with tibolone. Also, the mean endometrium width increased significantly from baseline to the end of treatment in the estrogen-progestin group, but not in the tibolone group. Conclusions: Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus and myomas. Copyright (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "Hormone replacement therapy, Menopause, Tibolone, Uterine myomas",
author = "Luigi Fedele and Stefano Bianchi and Ricciarda Raffaelli and Giovanni Zanconato",
year = "2000",
month = "1",
doi = "10.1016/S0301-2115(99)00115-3",
language = "English",
volume = "88",
pages = "91--94",
journal = "European Journal of Obstetrics, Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas

AU - Fedele, Luigi

AU - Bianchi, Stefano

AU - Raffaelli, Ricciarda

AU - Zanconato, Giovanni

PY - 2000/1

Y1 - 2000/1

N2 - Objective: To evaluate the effects of two types of hormone replacement therapy, an estrogen-progestin combination and tibolone, on uterine myomas in menopausal women. Study design: Thirty-eight menopausal women with one or more uterine myomas were randomized to treatment with a transdermal system continuously releasing estradiol 50 μg/day combined with oral medroxyprogesterone acetate (MPA) 10 mg/day for 12 days/month or tibolone tablets 2.5 mg/day. The scheduled duration of both treatments was 12 months. Physical examination and abdominal/transvaginal ultrasonography were performed before entering the study and at 3, 6 and 12 months of treatment. At each ultrasonography the overall uterine volume was determined as well as the size of each myoma and the endometrial thickness and characteristics. Results: No statistically significant difference was detected between the two groups at any time during treatment. However, within-group analysis showed a significant increase of uterine volume and of myoma number and size in the estrogen-progestin group, whereas no such increase occurred in the patients treated with tibolone. Also, the mean endometrium width increased significantly from baseline to the end of treatment in the estrogen-progestin group, but not in the tibolone group. Conclusions: Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus and myomas. Copyright (C) 2000 Elsevier Science Ireland Ltd.

AB - Objective: To evaluate the effects of two types of hormone replacement therapy, an estrogen-progestin combination and tibolone, on uterine myomas in menopausal women. Study design: Thirty-eight menopausal women with one or more uterine myomas were randomized to treatment with a transdermal system continuously releasing estradiol 50 μg/day combined with oral medroxyprogesterone acetate (MPA) 10 mg/day for 12 days/month or tibolone tablets 2.5 mg/day. The scheduled duration of both treatments was 12 months. Physical examination and abdominal/transvaginal ultrasonography were performed before entering the study and at 3, 6 and 12 months of treatment. At each ultrasonography the overall uterine volume was determined as well as the size of each myoma and the endometrial thickness and characteristics. Results: No statistically significant difference was detected between the two groups at any time during treatment. However, within-group analysis showed a significant increase of uterine volume and of myoma number and size in the estrogen-progestin group, whereas no such increase occurred in the patients treated with tibolone. Also, the mean endometrium width increased significantly from baseline to the end of treatment in the estrogen-progestin group, but not in the tibolone group. Conclusions: Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus and myomas. Copyright (C) 2000 Elsevier Science Ireland Ltd.

KW - Hormone replacement therapy

KW - Menopause

KW - Tibolone

KW - Uterine myomas

UR - http://www.scopus.com/inward/record.url?scp=0033988668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033988668&partnerID=8YFLogxK

U2 - 10.1016/S0301-2115(99)00115-3

DO - 10.1016/S0301-2115(99)00115-3

M3 - Article

C2 - 10659924

AN - SCOPUS:0033988668

VL - 88

SP - 91

EP - 94

JO - European Journal of Obstetrics, Gynecology and Reproductive Biology

JF - European Journal of Obstetrics, Gynecology and Reproductive Biology

SN - 0028-2243

IS - 1

ER -